Aprea Therapeutics (APRE) AI Stock Analysis

• Market Cap: $10.14M
• Dividend Yield: N/A
• Average Volume (3M): 55.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.86
• Revenue Growth: -62.75%
• EPS Growth: 23.87%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 11,451,118
• 10 Day Avg. Volume: 84,633
• 30 Day Avg. Volume: 55,770
• PEG Ratio: 0.03
• Price to Book (P/B): 0.94
• Price to Sales (P/S): 12.06
• P/FCF Ratio: -1.34
• Enterprise Value/Market Cap: -0.77
• Enterprise Value/Revenue: -15.98
• Enterprise Value/Gross Profit: 1.24
• Enterprise Value/Ebitda: 0.57
• 1Y Price Target: $5.33
• Price Target Upside: 505.68% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -1.18
• Revenue Forecast (FY): $300.00K

• Rating: 43 Neutral
• Price Target: $0.65 ▼(-26.25% Downside)
• Action: Reiterated Date: 01/31/26
• Date: Action: Reiterated 01/31/26

APRE scores low primarily due to weak financial performance (ongoing losses and cash burn with declining revenue) and bearish technicals (trading below key moving averages with negative MACD). Valuation provides limited support given negative earnings and no dividend yield data.

Positive Factors

Low debt balance sheet strength

A near-zero debt profile materially lowers refinancing and interest-rate risk for a clinical-stage biotech. With no scheduled debt service, management can prioritize R&D and trial funding, giving the company durable financial flexibility relative to highly leveraged peers during multi-year development cycles.

Focused DDR pipeline and strategy

Concentrating on DNA damage response (DDR) targets and synthetic lethality aligns the company with a validated oncology approach and growing unmet need. A clear roadmap and experienced management increase execution odds, enabling durable strategic focus on combinations and safer WEE1/ATR approaches that can sustain long-term clinical relevance.

Clinical progress in lead assets

Early efficacy signals and a recommended Phase 2 dose materially de-risk clinical development versus preclinical programs. Demonstrable human activity supports informed dose optimization, strengthens partnerability, and improves the longer-term probability of advancing to registrational studies or strategic collaborations that can sustain the business.

Negative Factors

Persistent negative cash flow

Meaningful negative operating and free cash flow indicates the company's R&D and operations are consuming cash faster than it generates it. Over a 2–6 month horizon this necessitates external financing, constrains strategic optionality, and increases execution risk if fundraising windows tighten or trial costs rise.

Declining revenue base

A shrinking and very small revenue base means the company lacks meaningful commercial cash generation to offset R&D burn. For a pre-commercial biotech, declining revenue reduces internal funding capacity and heightens dependency on capital markets, raising structural funding risk over the medium term.

Erosion of equity and funding reliance

Significant erosion of shareholders' equity reduces the balance-sheet buffer available for setbacks and amplifies the need for dilutive financing. Combined with recent private placements, this indicates a structural reliance on external capital that can dilute holders and complicate long-term planning if clinical timelines extend or costs increase.

Aprea Therapeutics Business Overview & Revenue Model

Company Description

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

How the Company Makes Money

Aprea Therapeutics makes money through the development and commercialization of its proprietary cancer therapeutics. The company generates revenue mainly from partnerships and collaborations with larger pharmaceutical companies, which may include license agreements, milestone payments, and royalties from the commercialization of its drug candidates. Aprea also seeks funding through grants and research collaborations to support its ongoing research and development efforts. Furthermore, successful clinical trials leading to market approval of its products can significantly increase its revenue through direct sales and licensing deals.

Aprea Therapeutics Financial Statement Overview

Summary

Financials reflect an early-stage, pre-commercial biotech: sharply declining trailing revenue, deeply negative profitability (TTM net loss about -$13M), and sustained cash burn (TTM free cash flow about -$13.5M). The balance sheet benefits from essentially no debt, but equity has eroded materially over time, increasing reliance on external funding.

Income Statement

APRE remains a pre-commercial biotech with a very small revenue base and persistent losses. Revenue declined sharply in TTM (Trailing-Twelve-Months) (about -42% vs. the prior period), and profitability is deeply negative with TTM (Trailing-Twelve-Months) net income around -$13.0M and negative operating results. A positive is that losses are far smaller than the extreme loss year seen in 2022, but the overall trajectory still shows limited revenue scale and continued cash burn-driven operating deficits.

Balance Sheet

The balance sheet is a relative strength due to essentially no debt (debt-to-equity at 0.0 in recent periods), which reduces refinancing and solvency risk. However, equity has declined materially over time (from ~$77.4M in 2020 to ~$11.6M in TTM (Trailing-Twelve-Months)), reflecting ongoing losses and erosion of the capital base. Returns on equity are consistently negative, underscoring that the company is not yet generating shareholder value from its asset base.

Cash Flow

Cash flow is weak with sustained negative operating and free cash flow (about -$13.5M in TTM (Trailing-Twelve-Months)). While free cash flow burn improved dramatically versus 2021–2022 levels, it remains meaningfully negative and implies continued reliance on external funding. Free cash flow roughly matches net loss (close to 1x), indicating reported losses are translating into real cash outflows rather than being cushioned by non-cash items.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	488.24K	1.50M	583.23K	0.00	0.00	0.00
Gross Profit	-6.27M	-7.86M	576.18K	-16.40M	-271.68K	-229.61K
EBITDA	-13.65M	-14.30M	-14.28M	-37.37M	-36.86M	-53.25M
Net Income	-13.04M	-12.96M	-14.29M	-112.66M	-36.54M	-53.92M
Balance Sheet
Total Assets	14.32M	23.98M	22.65M	30.16M	56.82M	92.81M
Cash, Cash Equivalents and Short-Term Investments	13.72M	22.85M	21.61M	28.79M	53.08M	89.02M
Total Debt	0.00	0.00	0.00	0.00	190.47K	335.16K
Total Liabilities	2.68M	4.67M	4.39M	4.51M	7.32M	15.41M
Stockholders Equity	11.64M	19.31M	18.26M	25.64M	49.51M	77.40M
Cash Flow
Free Cash Flow	-13.54M	-13.57M	-12.27M	-25.01M	-37.69M	-41.83M
Operating Cash Flow	-13.54M	-13.56M	-12.18M	-25.01M	-37.69M	-41.80M
Investing Cash Flow	0.00	-15.48K	-93.09K	0.00	0.00	-25.71K
Financing Cash Flow	945.82K	14.82M	5.14M	682.97K	1.75M	150.95K

Aprea Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.88
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APRE, the sentiment is Neutral. The current price of 0.88 is above the 20-day moving average (MA) of 0.73, above the 50-day MA of 0.82, and below the 200-day MA of 1.36, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 57.66 is Neutral, neither overbought nor oversold. The STOCH value of 94.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for APRE.

Aprea Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INAB	52 Neutral	$16.60M	-0.26	-189.72%	―	―	70.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VYNE	51 Neutral	$20.16M	-0.93	-70.67%	―	6.29%	7.42%
NCNA	46 Neutral	$8.95M	-0.01	-179.40%	―	―	94.52%
QNRX	44 Neutral	$5.01M	-0.02	-655.85%	―	―	-228.89%
APRE	43 Neutral	$10.14M	-0.41	-74.72%	―	-62.75%	23.87%

Aprea Therapeutics Corporate Events

Aprea Therapeutics Announces Financing and Early Trial Response

On January 28, 2026, Aprea Therapeutics entered into a securities purchase agreement with new and existing healthcare-focused institutional investors and company insiders for a $5.6 million private placement of 6,288,857 shares of common stock (or pre-funded warrants) and accompanying common stock purchase warrants, priced at the Nasdaq “at-the-market” minimum price of $0.89 per unit, with warrants exercisable at $0.765 per share for two years. The financing, expected to close on or about January 30, 2026, is structured with standard ownership caps, no price-reset or anti-dilution ratchets beyond customary adjustments, and registration rights for resale, and is accompanied by amended restrictions on future equity issuance; Aprea plans to use the net proceeds for general corporate purposes and research and development, including adding patients to key dose levels in its ongoing Phase 1 ACESOT-1051 study of APR-1051, where on January 29, 2026 it also reported a first unconfirmed partial response, a development that could support more robust dose optimization data and potentially strengthen the program’s value and clinical trajectory.

The most recent analyst rating on (APRE) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.

Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook

On January 9, 2026, Aprea Therapeutics updated its corporate presentation, outlining a development roadmap through 2026 that highlights multiple DDR-focused drug candidates and clinical milestones in early-stage oncology trials. The company detailed progress on its ATR inhibitor ATRN-119, for which further monotherapy enrollment has been paused in favor of exploring combination strategies, and on its WEE1 inhibitor APR-1051, which is being advanced toward clinical proof-of-concept as a potentially safer alternative in a target class historically limited by toxicity. The refreshed deck emphasizes Aprea’s strategy to capitalize on synthetic lethality as a validated cancer-killing approach, positioning the firm to benefit from rising global cancer incidence and sustained demand for targeted therapies, while showcasing an experienced management team and board with deep expertise in oncology drug development and commercialization.

The most recent analyst rating on (APRE) stock is a Hold with a $0.89 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.

Aprea Therapeutics Secures $3.1M in Private Placement

On December 8, 2025, Aprea Therapeutics entered into a securities purchase agreement with accredited investors and company insiders to issue and sell 2,623,023 shares of common stock and warrants in a private placement, expected to close on December 10, 2025, for approximately $3.1 million. This financing is anticipated to extend Aprea’s cash runway into Q1 2027, supporting its clinical programs and general corporate purposes, with Maxim Group LLC acting as the sole placement agent.

The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.

Aprea Therapeutics Reports Q3 Results and Clinical Updates

On November 12, 2025, Aprea Therapeutics reported its third-quarter financial results and provided updates on its clinical programs. The company highlighted progress in its WEE1 and ATR inhibitor programs, with APR-1051 showing promising results in a Phase 1 trial and ATRN-119 reaching a recommended Phase 2 dose. Aprea’s financials showed a reduction in operating loss and R&D expenses compared to the previous year, with cash reserves expected to support operations into late 2026.

The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.